Medindia LOGIN REGISTER
Medindia

Gene Therapy for Rare Eye Disease

by Colleen Fleiss on Jan 22 2023 8:55 PM
Listen to this article
0:00/0:00

Gene Therapy for Rare Eye Disease
Researchers believe that gene therapy might help restore vision loss in Usher Syndrome Type 2A (USH2A), a rare genetic disorder.

What is Usher Syndrome Type 2A, Rare Genetic Disease

Usher Syndrome Type 2A, caused by mutations of the USH2A gene, can include hearing loss from birth and progressive loss of vision, prompting retinitis pigmentosa (RP). RP affects the retina, the eye’s light-sensitive layer, leading to a breakdown of cells in the retina, which causes blindness. Currently no treatment exists for USH2A.
“Developing an effective treatment for USH2A has been challenging due to its large coding sequence (15.8 kb) that has precluded its delivery using standard approaches and the presence of multiple isoforms with functions that are not fully understood,” said Naash, who will also evaluate the long-term efficacy of the best therapeutic platform for future translation to the clinic.

To rescue vision loss, Naash’s non-viral therapy targets the mutation in usherin, the protein product that causes Usher Syndrome Type 2A. Naash has already cloned two usherin isoforms to be tested with her innovative platform to safely advance gene therapy for USH2A.

“Understanding which isoforms of usherin are expressed in the retina and the cochlea and what role they play (in contrast to mutant pathogenic forms) is essential in developing an effective gene therapy construct,” said Naash.

The work will provide a solid foundation for understanding the function of each usherin isoform and developing an effective gene therapy platform to treat USH2A associated visual defects, she said.

Source-Eurekalert


Advertisement